TXM Plant

TXM Plant

Keeping things moving Recognized for compliance, safety, and reliability within the rail industry, TXM Plant possesses one of the most…

More...
Tuffnells

Tuffnells

A bright future ahead for Tuffnells Tuffnells is embarking on the next phase of its transformative plan, readying the company…

More...
R McDowell Haulage & Distribution

R McDowell Haulage & Distribution

Logistic integrity Working with businesses of all sizes, from micro to blue chip, R McDowell Haulage & Distribution Ltd is…

More...
Linkline Transport

Linkline Transport

Driven by dedication Thanks to strong partnerships and strategic investments, Linkline Transport reinforced its position as Northamptonshire’s fastest growing privately…

More...
DP World Sokhna

DP World Sokhna

A gateway to the world A key part of DP World’s international network, DP World Sokhna is strategically located on…

More...
Challenge Group

Challenge Group

Rising to the challenge With operational hubs around the world supporting its tailor-made, door-to-door service, Challenge Group is on a…

More...
Biffa Waste Services Limited

Biffa Waste Services Limited

Badge of honor After successfully negotiating the Covid-19 outbreak and launching a brand-new sustainability strategy, Biffa Waste Services finished 2020…

More...
AO Logistics

AO Logistics

Let's go Offering next-day delivery to almost every UK postcode, on products from both AO and selected third-party clients, AO…

More...
 

FEATURED CONTENT

All Featured Content
 

EXCLUSIVE FEATURES

All Exclusive Features
 

TRUCKING / AIR / INFRASTRUCTURE / WAREHOUSING & SHIPPING / FLEET

 

Read All Trucking & Freight Read All Air Cargo  Read All Infrastructure

Read All Warehousing & Shipping Read All Fleet Management

Click here to advertise with us

newswirelogo

  • Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors

    EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced the appointment of Gil N Schwartzberg to its Board of Directors. Mr. Schwartzberg is filling a vacancy created by the resignation of Winson (Sze Chun) Ho, M.D.

  • BioSig Completes Enrollment in the PURE EP 2.0 Clinical Study

    Westport, CT, April 13, 2021 (GLOBE NEWSWIRE) --

    BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced it completed enrollment in the PURE EP 2.0 clinical trial.

  • Allworth Financial Partners with $340 Million RIA Shone Wealth Management
    The agreement expands Allworth’s footprint in the San Francisco Bay Area 
    The agreement expands Allworth’s footprint in the San Francisco Bay Area
  • NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLC

    SEOUL, South Korea, April 13, 2021 (GLOBE NEWSWIRE) -- NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, announced the expansion of its clinical trial and supply agreement with Merck KGaA, Darmstadt, Germany to conduct a Phase I/IIa open-label, single-center trial evaluating the safety and anti-tumor activity of SNK01 (autologous natural killer cells) in combination with either gemcitabine/carboplatin or gemcitabine/carboplatin plus cetuximab (ERBITUX®)* in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed after prior tyrosine kinase inhibitor (TKI) therapy. Preliminary in vitro data from an NKMax study suggested that EGFR-TKI resistant NSCLC cells highly express EGFR and are more efficiently killed by SNK01 in the presence of cetuximab through antibody-dependent cellular cytotoxicity (ADCC). Dr. Jae-Cheol Lee, M.D., Ph.D. from the Department of Oncology and Lung Cancer Center at Asan Medical Center, Seoul, Korea will be acting as principal investigator. This study was approved by Korea’s regulatory agency, MFDS, earlier this year as well as by the Asan Hospital IRB. The first patient will soon be enrolled.

  • Compliance Issues, Ransomware Headline Chicago Virtual Cybersecurity Summit
    Understanding New Regulatory Requirements and Managing Threats Remains Essential for IT Professionals 
    Understanding New Regulatory Requirements and Managing Threats Remains Essential for IT Professionals

Corporate Head Office

Transportation and Logistics International

Cringleford Business Centre
Intwood Road
Cringleford, Norwich, UK
NR4 6AU

Click here for a full list of contacts.

North American Office

Transportation and Logistics International

Finelight Media
207 E. Ohio Street Suite 351
Chicago, IL 60611


Click here for a full list of contacts.

Back To Top